Bruna Melchior Silva, None;
C Gustavo De Moraes, Belite (C), Carl Zeiss (C), Galimedix (C), Heidelberg (R), Novartis (C), Perfuse Therapeutics (C), Reichert (C), Topcon (R);
Jayter Paula, None;
George Cioffi, None;
Christopher Girkin, EyeSight Foundation of Alabama (F), GmbH (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindness (F);
Massimo Fazio, EyeSight Foundation of Alabama (F), GmbH (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindness (F);
James Proudfoot, None;
Robert Weinreb, Aerie Pharmaceuticals (C), Allergan (C), Bausch&Lomb (C), Bausch&Lomb (F), Carl Zeiss Meditec (F), Centervue (F), Eyenovia (C), Heidelberg Engineering (F), Konan Medical (F), Meditec-Zeiss (P), Optovue (F), Toromedes (P);
Linda Zangwill, Carl Zeiss Meditec Inc (F), GmbH (F), Heidelberg Engineering (F), Heidelberg Engineering (R), Meditec-Zeiss (P), National Eye Institute (F), Optovue Inc. (F), Topcon Medical Systems Inc (F);
Jeffrey Liebmann, Aeri (C), Alcon, Inc. (C), Allergan, Inc (C), Bausch & Lomb (C), Bausch & Lomb (F), Carl Zeiss Meditec (F), Carl Zeiss Meditech, Inc. (C), Eyenova (C), Galimedex (C), GmbH (C), Heidelberg Engineering (C), Heidelberg Engineering (F), National Eye Institute (F), Novartis (C), Optovue (F), Reichert (C), Reichert (F), Research to Prevent Blindness (F), Topcon (F), Valeant Pharmaceuticals (C)